ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 153,24
0,66%
DAX
17 896,50
-0,14%
Brent Oil
83,83
0,35%
Bitcoin
59 078,35
1,44%
Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. AMEX
  6. Navidea Biopharmaceuticals Inc (NAVB)

  7. Navidea Biopharmaceuticals Inc (NAVB) Actualités

NAVB Navidea Biopharmaceuticals Inc

0,0779
0,00 (0,00%)
Dernière mise à jour : 02:00:00
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Navidea Biopharmaceuticals Inc NAVB AMEX Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,00 0,00% 0,0779 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,0779
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
21/12/202321:32EDGAR2Form SC 13D/A - General statement of acquisition of..
06/12/202300:26EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/12/202317:49EDGAR2Form 8-K - Current report
16/11/202322:55EDGAR2Form 8-K - Current report
23/10/202319:56EDGAR2Form 25-NSE - Notification filed by national security..
06/10/202303:01BWNavidea Biopharmaceuticals, Inc. Announces NYSE American’s..
05/10/202322:21EDGAR2Form DEF 14A - Other definitive proxy statements
15/9/202321:42EDGAR2Form PRE 14A - Other preliminary proxy statements
11/9/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
15/8/202323:53EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/8/202322:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:29BWNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing..
08/8/202322:23EDGAR2Form 8-K - Current report
31/7/202315:32BWNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces..
29/7/202302:23BWNavidea Biopharmaceuticals, Inc. Announces NYSE American Has..
28/7/202323:10EDGAR2Form 8-K - Current report
27/7/202323:20BWNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as..
18/7/202300:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/7/202300:00EDGAR2Form 3 - Initial statement of beneficial ownership of..
13/7/202323:27EDGAR2Form 8-K - Current report
13/7/202323:09BWNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to..
06/7/202322:39EDGAR2Form 8-K - Current report
03/7/202323:30EDGAR2Form DEF 14A - Other definitive proxy statements
03/7/202322:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/6/202322:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
30/6/202316:46EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/6/202315:16BWNavidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer..
16/6/202322:54BWNavidea Biopharmaceuticals, Inc. Announces Distribution of..
16/6/202319:52BWNavidea Biopharmaceuticals, Inc. Receives $7.5 Million Cash..
07/6/202322:00BWNavidea Biopharmaceuticals, Inc. Reports First Quarter 2023..
02/6/202323:54BWNavidea Biopharmaceuticals, Inc. Receives NYSE American..
01/6/202323:53BWNavidea Biopharmaceuticals, Inc. Welcomes Jill Bieker..
23/5/202300:30BWNavidea Biopharmaceuticals, Inc. Investors Purchase $1.1..
11/5/202323:35BWNavidea Biopharmaceuticals, Inc. Promotes Michael Sherman..
08/5/202322:12BWNavidea Biopharmaceuticals, Inc. Drives Strategy Forward,..

Dernières Valeurs Consultées

AMEX
NAVB
Navidea Biopharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés